https://www.pharmaceutical-technology.com/data-insights/sintilimab-innovent-biologics-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/
Sintilimab is under clinical development by Innovent Biologics and currently in Phase II for Head And Neck Squamous Cell Carcinoma (HNSC).
innovent biologicssquamous cellsintilimabheadneck
https://www.nasdaq.com/market-activity/stocks/ivbiy/press-releases
Get the latest insights on Innovent Biologics Inc ADR (IVBIY) with press releases and corporate news to help you in your trading and investing decisions.
innovent biologicspress releasesincadrnasdaq
https://www.clinicaltrialsarena.com/news/innovent-biologics-plaque-psoriasis/
Innovent Biologics has dosed the first participant in the Phase III CLEAR clinical trial of picankibart in plaque psoriasis patients.
innovent biologicsplaque psoriasisbeginssubjectdosing
https://www.pharmaceutical-technology.com/data-insights/ibi-133-innovent-biologics-solid-tumor-likelihood-of-approval/
IBI-133 is under clinical development by Innovent Biologics and currently in Phase II for Solid Tumor.
innovent biologicssolid tumoribilikelihood
https://www.pharmaceutical-technology.com/data-insights/ibi-110-innovent-biologics-hepatocellular-carcinoma-likelihood-of-approval/
IBI-110 is under clinical development by Innovent Biologics and currently in Phase II for Hepatocellular Carcinoma.
innovent biologicshepatocellular carcinomaibilikelihood